Conformis announced that it has entered into a settlement and license agreement with Medacta USA, Medacta Germany GmbH, and Medacta International SA that resolves all patent disputes between the companies. Under the terms of the settlement, Medacta will receive a non-exclusive license to certain Conformis patents related to patient-specific instrumentation for use with off-the-shelf knee and shoulder implants.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CFMS:
- Conformis, Inc. Announces Settlement of Medacta Patent Litigation
- Conformis price target raised to $8.00 from $1.25 at Oppenheimer
- Conformis effects 1-for-25 reverse stock split
- Conformis Reports Third Quarter 2022 Financial Results
- Conformis, Inc. to Announce Financial Results for Its Third Quarter 2022